ReviewCurrent opinion in psychiatry2021
Schizophrenia during the COVID-19 pandemic.
Review in Current opinion in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2022Pooled it
- Schizophrenia-related suicide mortality in the United States by sex, 1999-2023.Discover mental health · 2026Article
- Burden, Incidence, and Spatial Distribution of Schizophrenia in Ecuador (2010-2021): A Nationwide Hospital Discharge Analysis.International journal of environmental research and public health · 2026Observational
- Predicting Physical Aggression among Schizophrenia Patients in Rural Communities of Southwestern China.Alpha psychiatry · 2025Article
- Hematological and biochemical markers and cytokine levels in hospitalized psychiatric patients with COVID-19.Frontiers in immunology · 2025Article
- Editorial: Cognitive and mental health improvement under- and post-COVID-19, volume II.Frontiers in psychology · 2025Article
- Editorial: Cognitive and mental health improvement under- and post-COVID-19.Frontiers in psychology · 2025Article
- Trends in incidence, prevalence, and disability-adjusted life years of schizophrenia in China from 1990 to 2021, with projections for 2022-2050.Frontiers in psychiatry · 2025Article
- Associations Between Psychosocial Influence, Positive Thinking, and Vaccine Attitudes in Patients with Schizophrenia During the COVID-19 Pandemic.Psychology research and behavior management · 2025Article
- Treatment of Cognitive Impairment Associated with Schizophrenia Spectrum Disorders: New Evidence, Challenges, and Future Perspectives.Brain sciences · 2024Review
- Symptom Exacerbations of Patients Attending a Community Mental Health Center During the COVID-19 Pandemic.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2024Article
- Global research in schizophrenia and serotonin: a bibliometric analysis.Frontiers in psychiatry · 2024Review
- Abnormal Serum Biochemical Results and Mitochondrial Damage of Lymphocytes in Patients with Schizophrenia and SARS-CoV-2 Infection: A Retrospective Study.Neuropsychiatric disease and treatment · 2024Article
- Social networks use in the context of Schizophrenia: a review of the literature.Frontiers in psychiatry · 2024Review
- Article
- Schizophrenia and COVID-19: A bibliometric analysis of trends and themes.Schizophrenia research · 2023Article
- How did the Covid-19 pandemic affect individuals with schizophrenia from Turkey?The International journal of social psychiatry · 2023Article
- Schizophrenia as metabolic disease. What are the causes?Metabolic brain disease · 2023Review
- Changes in emergency psychiatric consultations in time of COVID-19: a retrospective observational study in the Verona Academic Hospital over the two pandemic years 2020-2021.BMC emergency medicine · 2023Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe coronavirus disease 19 (COVID-19) pandemic is having a critical impact on healthcare systems across the world, as well as on mental health in the general population; however, evidence regarding the impact of the COVID-19 pandemic on people living with schizophrenia and on the onset of psychotic symptoms is currently emerging. RECENT
findingsPeople living with schizophrenia are at an increased risk of COVID-19 and present worse COVID-19-related outcomes, including mortality. They show low levels of information and of concern regarding the possibility of contagion and infection but presented substantially stable levels of psychotic symptoms and even increased subjective well being during the pandemic. SARS-CoV-2, as well as the prolonged social isolation and the spread of misinformation, appear to be responsible in some cases for the onset of psychotic symptoms. SUMMARY: Clinicians should inform and educate their patients on the risks related to SARS-CoV-2 infection and COVID-19 and on the precautions that they should adopt to avoid contagion. Particular attention should be devoted to maintaining the continuity of care, especially in frail patients. Telemedicine might represent a valid support, but face-to-face visits in some cases remain essential. The hypothesis of a direct role of viral infection on the onset of psychotic disorders is currently debated, as viral involvement of central nervous system appears to be rather infrequent in COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.